"Breast Cancer: Its Link to Abortion and the Birth Control Pill"
Author: Chris Kahlenborn, M.D. (Internal Medicine)
Book is available online at Amazon at http://www.amazon.com/Breast-Cancer-Abortion-Birth-Control/dp/0966977734/ref=sr_1_1?ie=UTF8&qid=1349588285&sr=8-1&keywords=kahlenborn
ISBN-10: 0966977734
ISBN-13: 978-0966977738
Dr. Chris Kahlenborn has his own website: http://www.polycarp.org/overviewabortionbreastcancer.htm
To read more on how oral contraceptives act as a carcinogenic steroid, visit http://www.abortionbreastcancer.com/download/HeartbeatCareNetSteroidart091005.pdf
Here's a link to a year 2012 article titled, "Study Finds a Link Between Injectable Contraceptive Use and Increased Risk of Breast Cancer in Young Women" https://www.fhcrc.org/en/news/releases/2012/04/dmpa-breast-cancer-risk-chris-li.html Here's a link to the study http://cancerres.aacrjournals.org/content/early/2012/02/25/0008-5472.CAN-11-4064.abstract
[from 1 Nov 2010, http://breastcancerawarenessnews.blogspot.com/ ]
###################################################################################
BREAST CANCER
PDF: German Study: The Earlier OCP (Oral Contraceptive Pill) Started, the Higher the Breast Cancer Risk
Abstract
Breast cancer is progressively diagnosed with increasing age. This study aimed to determine whether women who started using the oral contraceptive pill (OCP) at an early age developed breast cancer earlier than women who started using the OCP later in life. A database review of 1,010 breast cancer patients, who had used the OCP at some point in their life, was carried out.
Associations of age at OCP start with age at breast cancer diagnosis were determined by multiple linear regression analysis, considering year of birth, year of diagnosis, age at first pregnancy, number of live births, age at menarche, and length of OCP use.
There was evidence of a linear trend between age at OCP start and age at breast cancer diagnosis. Women who started using the OCP aged 18 years or younger were, on average, 4 years younger at breast cancer diagnosis than women who started using the OCP over the age of 30 years, and women who started using the OCP aged 22–25 years were, on average, 3 years younger (p-value for trend <0.001).
The age when the OCP was started was positively associated with the age when breast cancer was first diagnosed.
[From beginning of Study Article]
A number of factors have been identified that potentially increase the risk of breast cancer development in younger patient groups. Early menarche (1,2), first child at a late age (3,4), use of the oral contraceptive pill (OCP) (5), a positive family history of breast cancer (6) and taller height (7,8) all seem to be associated with a higher disease risk.
Breast feeding (9), increased number of children (3,4), and a high body mass index (BMI) in pre-menopausal patients (10) have been shown to be protective. Only a few studies have, however, looked at potential relationships between initial age at exposure to a risk factor and subsequent age at breast cancer diagnosis.
Previous reports from this unit have suggested that an early menarche (11) and an early start to the OCP lead to earlier onset of breast cancer (12).
The present study focuses on women with a history of OCP use who had all developed breast cancer later in life. It aims to evaluate any correlation between the age when the OCP was started and the age when breast cancer was diagnosed. Other known risk factors for early onset breast cancer were considered.
[2011 The Breast Journal, Imkampe and Bates, Breast Unit, William Harvey Hospital, Ashford, Kent, United Kingdom,
DOI: 10.1111/j.1524-4741.2011.01181.x
Wiley Periodicals, Inc., 1075-122X/11
The Breast Journal, 2011, 1–6 ]
################################################################################
Online materials explaining the abortion – breast cancer link
and oral contraceptive – breast cancer link…
http://www.bcpinstitute.org/onlinepub.htm
############################################################
PROSTATE CANCER
Ecological Study: Oral Contraceptives and Prostate Cancer Link
[Comment: Medscape is definitely not prolife so this article is even more amazing. N Valko RN]
The Pill and Prostate Cancer: Is There a Link?
Countries where oral contraceptive use among women is high appear to have correspondingly higher rates of prostate cancer, according to a study published online
[http://bmjopen.bmj.com/content/1/2/e000311.full] November 14 in BMJ Open.
Several recent studies have suggested that estrogen exposure increases the risk for prostate cancer, David Margel, MD, from the Princess Margaret Hospital, University of Toronto, Ontario, Canada, told Medscape Medical News.
This could be because the residue of estrogen ends up in the water supply and the food chain, he said.
"We believe that this is due to an environmental effect," Dr. Margel said. "These oral contraceptives contain a small amount of estrogenic compounds, which are not biodegradable and are excreted in the urine. Although each woman takes these compounds at very minimal doses, when millions of women take them, and for a long period of time, there may be some effect on the environment."
Together with coauthor Neil E. Fleshner, MD, head of the division of urology at the University of Toronto Health Sciences Center, Dr. Margel decided to examine this association in an ecological study.
They used data from the International Agency for Research on Cancer to examine age-standardized rates of prostate cancer in 2007, and data from the United Nations World Contraceptive Use 2007 report to determine the proportion of women taking the birth control pill or using other means of contraception, including condoms, intrauterine devices (IUDs), and vaginal barriers.
They then analyzed the data for 87 countries, and correlated the percentage of oral contraceptive use with the number of new cases of prostate cancer and the number of deaths due to prostate cancer in each country.
They found that the use of IUDs, condoms, and other vaginal barriers was not associated with an increased risk for prostate cancer.
However, throughout the world, oral contraceptive use was associated with a significantly increased incidence of prostate cancer (r = 0.61; P < .05) and death from prostate cancer (r = 0.53; P < .05).
The researchers controlled for each country's wealth, but found no correlation between wealth and prostate cancer risk or mortality. However, "wealth may be associated with prostate cancer, because the wealthier the country, the higher the likelihood of screening for prostate cancer, and with screening comes more prostate cancer," Dr. Margel said.
He stressed that these findings are observational and do not indicate a cause-and-effect relation between oral contraceptive use and prostate cancer.
Importantly, "we are in no way telling women to get off the Pill," he added.
"In the future, to help us understand this phenomenon, we want to look at water supplies and test the estrogenic levels. We also want to look at prostate tissue to see if there are differences in estrogenic levels between those with prostate cancer and those without," Dr. Margel said.
For now, the study is just meant to cause people to take note of a potential harmful effect that the use of estrogen-disruptive compounds might be having.
"We hope this provokes other people to become interested in this topic, not only for oral contraceptives but for other endocrine-disruptive compounds that may be in the environment and may affect our health," Dr. Margel said…
…"All these data can tell you is that, on average, countries with higher oral contraceptive use have a higher prostate cancer incidence. This relationship could have many explanations, even at the country level, as they only controlled for gross domestic product per capita," Dr. van Wijngaarden said.
Like Dr. Yuan, Dr. van Wijngaarden believes that the study has generated an interesting hypothesis, "which is the only thing papers like this can do." However, he said, "it is far removed from being able to say that oral contraceptive use and prostate cancer are linked on a population level, let alone causally on an individual level."
Dr. Margel, Dr. Fleshner, Dr. Yuan, and Dr. van Wijngaarden have disclosed no relevant financial relationships.
BMJ Open. 2011;1:e000311. Full text
[Fran Lowry, November 16, 2011, From Medscape Medical News > Oncology, http://www.medscape.com/viewarticle/753667?sssdmh=dm1.734732&src=nldne]
BMJ Open. 2011;1:e000311 — BMJ Open 2011;1:e000311 doi:10.1136/bmjopen-2011-000311
Published 14 Nov 2011, Occupational & environmental medicine
Oral Contraceptive Use is Associated with Prostate Cancer: an Ecological Study
http://bmjopen.bmj.com/content/1/2/e000311.full
http://bmjopen.bmj.com/content/1/2/e000311.full
ABSTRACT
Background Several recent studies have suggested that oestrogen exposure may increase the risk of prostate cancer (PCa).
Objectives To examine associations between PCa incidence and mortality and population-based use of oral contraceptives (OCs). It was hypothesised that OC by-products may cause environmental contamination, leading to an increased low level oestrogen exposure and therefore higher PCa incidence and mortality.
Methods The hypothesis was tested in an ecological study. Data from the International Agency for Research on Cancer were used to retrieve age-standardised rates of prostate cancer in 2007, and data from the United Nations World Contraceptive Use 2007 report were used to retrieve data on contraceptive use. A Pearson correlation and multivariable linear regression were used to associate the percentage of women using OCs, intrauterine devices, condoms or vaginal barriers to the age standardised prostate cancer incidence and mortality. These analyses were performed by individual nations and by continents worldwide.
Results OC use was significantly associated with prostate cancer incidence and mortality in the individual nations worldwide (r=0.61 and r=0.53, respectively; p<0.05 for all). PCa incidence was also associated with OC use in Europe (r=0.545, p<0.05) and by continent (r=0.522, p<0.05). All other forms of contraceptives (ie, intra-uterine devices, condoms or vaginal barriers) were not correlated with prostate cancer incidence or mortality. On multivariable analysis the correlation with OC was independent of a nation's wealth.
Conclusion A significant association between OCs and PCa has been shown. It is hypothesised that the OC effect may be mediated through environmental oestrogen levels; this novel concept is worth further investigation.
From Full Text:
Discussion
In this study we have shown a strong correlation between the country-specific female OC use and incidence of prostate cancer among worldwide, continent and even intra-European nations. This correlation appeared specific to OC as no association was demonstrated with other forms of contraception such as intrauterine devices, condoms or vaginal barriers. Furthermore, prostate cancer mortality was also associated with OC use when examined globally. The correlation to OC use was independent of GDP as a measure of a country's wealth, and strongest in Europe..
Another plausible explanation for the association between OC use and prostate cancer is the potential environmental impact of OCs. The last two decades have witnessed growing scientific concerns and public debate over the potential adverse effects that may result from exposure to a group of chemicals that have the potential to alter the normal functioning of the endocrine system in wildlife and humans.
These chemicals are typically known as endocrine disturbing compounds (EDCs). Temporal increases in the incidence of certain cancers (breast, endometrial, thyroid, testis and prostate) in hormonally sensitive tissues in many parts of the industrialised world are often cited as evidence that widespread exposure of the general population to EDCs has had adverse impacts on human health.
OCs in use today can potentially act as EDCs as they frequently contain high doses of ethinyloestradiol, which is excreted in urine without degradation.
This can then end up either in the drinking water supply or passed up the food chain.11
OCs were made publicly available in the 1960s, and have been widely used since the 1980s, hence the exposure to these substances, even in small quantities, may be chronic enough (20–30 years) to have a clinically significant effect…
[Note: 88 countries in 18 continental areas were analyzed using data on prostate cancer from the International Agency for Research on Cancer, and the United Nations World Contraceptive Use 2007 report to retrieve data on contraceptive use.]
[http://bmjopen.bmj.com/content/1/2/e000311.full ; N Valko RN, 16 Nov 11]
http://bmjopen.bmj.com/content/1/2/e000311.full
BMJ Ecological Study: Oral Contraceptives and Prostate Cancer Connection
http://www.physiciansforlife.org/ecological-study-oral-contraceptives-and-prostate-cancer-connection-nov-2011-bmj/
#####################################################
BREAST CANCER
Breast Cancer & Milk Products
A February 16, 2009 visit to the Susan Komen website reveals that YOPLAIT YOGURT is a member of Komen's "Million Dollar Council Elite" and the "National Presenting Sponsor" of the Komen organization.
YOPLAIT is there at every Susan Komen walk and event to distribute complimentary portions of breast cancer fuel (yogurt) for those women who ignorantly donate their time and dollars to a self perpetuating organization of doom.
Faced with scientific evidence linking dairy consumption to breast cancer, who in their right mind would purchase yogurt to prevent breast cancer? American women, that's who.
Each sip of cow's milk contains estrogen, which has been identified as a key factor in promoting breast cancer cell growth. Milk also contains a powerful growth hormone called insulin-like growth factor (IGF-I).
There are hundreds of millions of different proteins in nature, and only one hormone that is identical between any two species. That powerful growth hormone is IGF-I, and it is an exact match in the cow's body and the human body.
Drink one glass of cow's milk and a female doubles the amount of free circulating IGF-I in her body.
Eat one portion of ice cream and one consumes 12 times the amount of this powerful breast cancer accelerator. IGF-I survives digestion and has been identified as the key factor in breast cancer's growth.
If you believe that breast feeding "works" to protect lactoferrins and immunoglobulins from digestion (and benefit the nursing infant), you must also recognize that milk is a hormonal delivery system. By drinking cow's milk or eating ice cream, one delivers IGF-I in a bioactive form to the body's cells. When IGF-I from cow's milk alights upon an existing cancer…
____________________________________________
"Human Insulin-like growth factor (IGF-I) and bovine IGF-I are identical. Both contain 70 amino acids in the identical sequence."
Judith C. Juskevich and C. Greg Guyer. SCIENCE,
vol. 249. August 24, 1990.
____________________________________________
"IGF-I is critically involved in the aberrant growth of human breast cancer cells."
M. Lippman. J. Natl. Inst. Health Res., 1991, 3.
____________________________________________
"Estrogen regulation of IGF-I in breast cancer cells would support the hypothesis that IGF-I has a regulatory function in breast cancer."
A.V. Lee, Mol-Cell- Endocrinol., March, 99(2).
____________________________________________
"IGF-I is a potent growth factor for cellular proliferation in the human breast carcinoma cell line."
J.C. Chen, J-Cell-Physiol., January, 1994, 158(1)
____________________________________________
"Insulin-like growth factors are key factors for breast cancer growth."
J.A. Figueroa, J-Cell-Physiol., Nov., 1993, 157(2)
____________________________________________
"IGF-I produces a 10-fold increase in RNA levels of cancer cells. IGF-I appears to be a critical component in cellular proliferation."
X.S. Li, Exp-Cell-Res., March, 1994, 211(1)
____________________________________________
"IGF-I plays a major role in human breast cancer cell growth."
E.A. Musgrove, Eur-J-Cancer, 29A (16), 1993
____________________________________________
"IGF-I has been identified as a key factor in breast cancer."
Hankinson. The Lancet, vol. 351. May 9, 1998
____________________________________________
"Serum IGF-I levels increased significantly in milk drinkers, an increase of about 10% above baseline but was unchanged in the control group."
Robert P. Heaney, Journal of the American Dietetic Association, vol. 99, no. 10. October 1999
____________________________________________
"IGF-1 accelerates the growth of breast cancer cells."
M. Lippman Science, Vol. 259, January 29, 1993
____________________________________________
* * * * * * * * * *
"Everyone should know that most cancer research is largely a fraud, and that the major cancer research organizations are derelict in their duties to the people who support them."
– Linus Pauling
Robert Cohen
http://www.notmilk.com
[March 05, 2010]
Forwarded by John E. Lewis, Ph.D.
Assistant Professor
Director of Research for Complementary and Integrative Medicine
Associate Director of the Medical Wellness Center
University of Miami School of Medicine
Clinical Research Building
Miami, FL 33136
[March 7, 2010, forwarded by John E. Lewis, Ph.D.]